Despite Challenges, Experts Optimistic About MS Therapy's Fu

Since the emergence of the first therapy, more than 20 agents with moderate to high efficacy have come to market for relapsing multiple sclerosis – but experts say that's both a blessing and problem.

Related Keywords

New York , United States , Patchogue , Mark Gudesblatt , Fredd Lublin , Shore Neurologic Associates In Patchogue , Drug Administration , Ms Care Center , Corinne Goldsmith Dickinson Center , Multiple Sclerosis , Mount Sinai , South Shore Neurologic Associates , Multiple Sclerosis Ms , Us , Interferon Beta , Fn Beta , Multiple Sclerosis Relapse , S Relapse , Elapse Of Multiple Sclerosis , Elapse Of Ms , Facial , Pathogenesis , Prognosis , Cognitive Impairment , Genetic Disorder , Biologic Therapy , Blood , Disability , Disease Modifying Therapy , Mt , Genetics , Glatiramer Acetate , Impairment , Insurance , Movement Disorder , Myelin , Tolerance , Young Adult , G ,